Hodgkin’s Lymphoma Medication and Treatment Regimens

Hodgkin’s lymphoma is treated with a combination of chemotherapy drugs, and increasingly with targeted therapies or immune checkpoint inhibitors added to the mix. The specific regimen depends on disease stage, the patient’s age, and how the tumor responds to early cycles of treatment. Cure rates are among the highest of any cancer, but the choice of medication matters because the drugs carry real long-term risks, and the field has shifted rapidly in recent years toward regimens that aim to maintain those high cure rates while reducing toxicity.

The Backbone Regimen and Its Main Rival

For decades, the standard chemotherapy combination for classic Hodgkin lymphoma has been ABVD, which stands for four drugs given together: doxorubicin, bleomycin, vinblastine, and dacarbazine. It remains effective and widely used, especially for early-stage disease. For advanced-stage disease, a more intensive regimen called escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone) has long been the main alternative. BEACOPP controls tumors better up front, but the question has always been whether that initial advantage translates into more people surviving long-term.

A large randomized trial comparing the two found that the seven-year rate of freedom from first progression was 85% with BEACOPP and 73% with ABVD, a clear early advantage. But after patients who relapsed on ABVD received salvage therapy, the seven-year overall survival rates converged: about 89% with BEACOPP and 84% with ABVD, a difference that was not statistically significant.¹ A separate multicenter European study confirmed this pattern: BEACOPP produced a higher rate of complete metabolic remission on PET scans and fewer relapses among those who did achieve remission, but overall survival was virtually identical between the two groups at eight years of follow-up.²

The tradeoff is toxicity. Escalated BEACOPP is significantly more myelosuppressive, meaning it hits the bone marrow harder, and carries higher rates of serious infections and secondary cancers.³ Because long-term survival is similar once salvage options are factored in, ABVD has remained the more common first choice in many countries, particularly for patients who would tolerate a rescue strategy if needed.

Adding Brentuximab Vedotin to the Mix

The first major shift away from pure chemotherapy came with brentuximab vedotin, a drug that targets a protein called CD30 found on the surface of Hodgkin lymphoma cells. It works as a kind of Trojan horse: the antibody portion latches onto CD30, the whole molecule gets pulled inside the cell, and a potent cell-killing agent is released internally, destroying the cancer cell from within.⁴ Because CD30 is expressed on the tumor cells but not on most healthy tissues, this targeting mechanism reduces some of the collateral damage of traditional chemotherapy. There is also evidence that the released toxin can leak out and kill neighboring support cells in the tumor’s microenvironment, a so-called bystander effect that may help explain its potency.⁵

The landmark ECHELON-1 trial tested brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine (a regimen called A+AVD, which essentially swaps brentuximab for the bleomycin in ABVD) against standard ABVD in patients with stage III or IV disease. At two years, the modified progression-free survival rate was about 82% with A+AVD versus 77% with ABVD.⁶ With five years of follow-up, that advantage held and widened somewhat to about 82% versus 75%, and fewer secondary malignancies were observed in the A+AVD group.⁷

The main downside is peripheral neuropathy, a tingling, numbness, or pain in the hands and feet that affected roughly two-thirds of patients receiving A+AVD in the ECHELON-1 trial.⁸ Most cases improve or resolve over time, but managing it requires close monitoring and sometimes dose reduction or stopping the drug early.⁹

Nivolumab Is Changing the Standard of Care

The newest and arguably most important development in Hodgkin lymphoma treatment is the addition of nivolumab, an immune checkpoint inhibitor, to first-line chemotherapy. Classic Hodgkin lymphoma has a genetic quirk that makes it particularly vulnerable to this class of drug. The malignant Reed-Sternberg cells almost universally carry extra copies of a chromosomal region that encodes proteins called PD-L1 and PD-L2. These proteins act like an “off switch” for immune cells, telling them to stand down even though cancer is present.¹⁰ Nivolumab blocks PD-1, the receptor on immune cells that reads that “off” signal, re-enabling the immune system to attack.

The SWOG S1826 trial compared nivolumab plus AVD (N+AVD) against brentuximab vedotin plus AVD (BV+AVD) in previously untreated advanced-stage patients. The results were striking: with about two years of follow-up, two-year progression-free survival was 92% with N+AVD versus 83% with BV+AVD.¹¹ The benefit held across subgroups. In adolescents, three-year progression-free survival was 93% with N+AVD versus 82% with BV+AVD.¹² In older adults, the gap was even more dramatic: two-year progression-free survival of 89% with N+AVD versus 64% with BV+AVD, along with fewer treatment-related deaths.¹³

Nivolumab also caused less neuropathy than brentuximab vedotin. The main immune-related side effect was thyroid dysfunction, seen in about 7% of adolescent patients, which is generally manageable.¹⁴ Based on these results, N+AVD is rapidly being adopted as the new standard for advanced-stage classic Hodgkin lymphoma in patients fit enough for combination chemotherapy.¹⁵

Tailoring Treatment Based on Early Scans

One of the more practical advances in how medications are used involves response-adapted therapy. After two cycles of treatment, patients typically get a PET-CT scan to see how the tumor is responding. If the scan comes back negative (meaning no active disease is detected), doctors can consider de-escalating treatment to spare patients from unnecessary drug toxicity. The most common version of this involves dropping bleomycin, the drug most associated with lung damage, from the remaining cycles of ABVD.

A major trial tested this approach in advanced-stage disease and found that dropping bleomycin after a negative interim PET scan resulted in less pulmonary toxicity without significantly reducing how well treatment worked. With extended follow-up of about seven years, the difference in three-year progression-free survival between patients who continued full ABVD and those who switched to AVD was just over one percentage point, well within the margin of noninferiority.¹⁶ The same principle has been applied in limited-stage disease, where omitting bleomycin after a negative PET scan following two cycles preserved excellent outcomes while reducing lung problems.¹⁷

On the other side, patients whose interim PET scan is still positive can have their therapy escalated to a more intensive regimen like BEACOPP. This response-adapted approach tries to spare people who are already responding well from excess toxicity while intensifying treatment for those who need it.¹⁸

When First-Line Treatment Fails

About 10-20% of patients with classic Hodgkin lymphoma relapse or do not respond fully to initial therapy.¹⁹ The standard approach for these patients involves salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant, which cures roughly half to 60% of them. Adding brentuximab vedotin or checkpoint inhibitors to the salvage phase has improved the odds: nearly two-thirds of patients can now achieve a PET-negative status before transplant, which is a strong predictor of long-term survival.²⁰

For patients who relapse even after transplant, or who are not candidates for transplant, checkpoint inhibitors like nivolumab and pembrolizumab have become important options, given the biological vulnerability of Hodgkin lymphoma cells described earlier. CAR-T cell therapy, which engineers a patient’s own immune cells to target CD30 on tumor cells, is another emerging approach. A meta-analysis of CD30-directed CAR-T trials in relapsed or refractory disease found an overall response rate of about 57%, with roughly a third of patients achieving complete remission. The one-year overall survival was about 89%, though one-year progression-free survival was lower at around 39%, suggesting many patients responded initially but relapsed again.²¹ One trial using fludarabine-based preparation before CAR-T infusion reported a 72% overall response rate and a 59% complete response rate, with only mild cytokine release syndrome.²² CAR-T for Hodgkin lymphoma is still evolving, with newer designs showing better persistence in the body and more effective tumor targeting in preclinical work.²³

Long-Term Side Effects That Shape Treatment Choices

Because Hodgkin lymphoma is typically diagnosed in young adults and cure rates are high, the medications used have to be weighed not just for their ability to kill cancer but for what they do to the body over the next several decades. This is where many of the treatment decisions really get made.

Lung and heart damage are real risks of ABVD-based regimens, particularly when combined with chest radiation. In a long-term follow-up study of patients treated with four cycles of ABVD and radiotherapy, about 8% developed pulmonary toxicity (ranging from temporary cough and shortness of breath to permanent lung fibrosis) and about 10% developed cardiovascular problems including heart attacks, heart failure, and valve disease. The cumulative risk of a cardiovascular event reached 14% at twelve years. These complications were linked to higher radiation doses and the cumulative doses of bleomycin and doxorubicin.²⁴

Secondary cancers are the other major long-term concern. A Dutch study tracking patients for up to 40 years after treatment found that the cumulative incidence of developing a second cancer reached nearly 49% at 40 years, with the risk still elevated more than 35 years out from treatment.²⁵ Breast cancer is the most common secondary solid tumor, and higher radiation doses and more radiation courses increase the risk substantially.²⁶ Combined chemotherapy and radiation carries a higher risk than radiation alone.²⁷ These numbers come mostly from eras when radiation fields were larger and doses higher than what is used today, so the risk for patients treated with modern protocols should be lower, but the concern has not disappeared and drives the push toward less radiation and less toxic drugs.

Fertility and Chemotherapy

Fertility is one of the most personal consequences of treatment choice. A systematic review and meta-analysis found that the overall rate of infertility after Hodgkin lymphoma chemotherapy was about 21% in women and 49% in men, but those averages hide enormous variation by regimen. ABVD had the lowest impact, with infertility rates around 7% in women and 9% in men. BEACOPP was far harsher, with infertility affecting roughly 39% of women and 77% of men. Older alkylating-agent-based regimens like MOPP and COPP fell in between, with rates around 32% in women and 75% in men.²⁸

Age is a significant modifier, especially for women. Those over 30 face a substantially higher risk of premature ovarian failure even with ABVD. Men face a high risk of prolonged azoospermia with any regimen containing procarbazine or cyclophosphamide, the alkylating agents found in BEACOPP and older protocols. Sperm banking should be discussed before starting any of these regimens, and fertility preservation counseling is strongly recommended before BEACOPP or salvage therapy involving high-dose chemotherapy and transplant.²⁹ For patients receiving ABVD, the fertility risk is low enough that a “wait and see” approach after treatment may be reasonable, particularly for younger women, rather than rushing into egg freezing before the diagnosis is even fully processed.

Treating Children and Adolescents

Pediatric Hodgkin lymphoma is highly curable, but the stakes of late effects are even higher because survivors have so many decades ahead of them. Treatment strategies for young patients have been refined over successive clinical trials to reduce cumulative exposure to the drugs most likely to cause lasting harm, particularly alkylating agents, anthracyclines like doxorubicin, and radiation.³⁰ The arrival of brentuximab vedotin and checkpoint inhibitors has given pediatric oncologists new tools for de-escalation, potentially replacing some of the traditional chemotherapy backbone with targeted agents that carry different (and in some cases milder) toxicity profiles.³¹ Risk-stratified and response-adapted approaches are especially important here, as they allow treatment intensity to be calibrated to what each patient’s disease actually requires rather than applying the same protocol to everyone.

Older Adults and People Living with HIV

Age is one of the strongest predictors of how well a patient tolerates Hodgkin lymphoma treatment. Older adults are more likely to have underlying heart, lung, or kidney problems that make intensive chemotherapy dangerous. Dose reductions and regimen modifications are common. The S1826 trial data in patients over 60 showed that N+AVD was not only more effective than BV+AVD in this group but also far better tolerated: 69% of older patients completed six full cycles of N+AVD without dose reduction, compared to just 26% with BV+AVD. Nonrelapse mortality was 6% with N+AVD versus 16% with BV+AVD.³² These results suggest that N+AVD may be particularly well-suited for older patients, a group that has historically had worse outcomes due to treatment intolerance.

Patients living with HIV can now expect treatment outcomes comparable to those of the general population, thanks to modern antiretroviral therapy. The key challenge is managing drug-drug interactions between HIV medications and chemotherapy, which can affect both the efficacy of cancer treatment and the toxicity profile. Meticulous attention to pharmacokinetics is required, and supportive care (prophylactic antibiotics, growth factor support) tends to be more aggressive.³³ The same standard regimens are used, but the margin for error in dose management is narrower.³⁴

Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Not all Hodgkin lymphoma is the same. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype that behaves quite differently from classic Hodgkin lymphoma. The malignant cells in NLPHL express B-cell markers rather than the CD30 and CD15 seen in classic disease, which means the targeted therapies that work for classic Hodgkin lymphoma are not always appropriate here.³⁵

Instead, rituximab, an antibody targeting the B-cell marker CD20, has become a central part of NLPHL treatment. In a small study comparing rituximab-based treatment to a historical cohort given ABVD plus radiation, patients on the rituximab regimen had a 100% progression-free survival rate at seven years versus 66% for the chemotherapy group.³⁶ The catch is that rituximab alone, without chemotherapy, tends to have a shorter progression-free survival, with one report showing only about 51% at ten years when used as a single agent. Overall survival remains excellent regardless, because patients respond to later treatments when they relapse.³⁷ NLPHL is a disease where oncologists often accept a higher relapse rate in exchange for using gentler therapies, banking on the fact that salvage options work well and overall survival stays very high.

Tracking Response with Circulating Tumor DNA

PET-CT scans are the current gold standard for evaluating whether treatment is working, but they require a trip to a radiology center and expose patients to radiation. Circulating tumor DNA, fragments of cancer cell DNA found in the blood, is being studied as a complement or potential alternative. In one study of classic Hodgkin lymphoma patients, ctDNA levels tracked closely with PET-CT findings over time, rising when disease was active and falling with successful treatment.³⁸ If this approach is validated in larger studies, it could eventually allow doctors to monitor treatment response with a simple blood draw, potentially catching relapses earlier and guiding therapy adjustments faster than periodic imaging alone.

Cost Considerations for Newer Regimens

With the shift toward expensive targeted and immunotherapy agents, cost has become part of the treatment conversation. A cost-effectiveness analysis comparing N+AVD to BV+AVD found highly variable results depending on drug pricing and the healthcare system in question. In the United States, the incremental cost ranged from substantial savings to significant added expense depending on modeling assumptions, with cost-effectiveness ratios spanning from clearly dominant (N+AVD both cheaper and more effective) to borderline.³⁹ What drives the numbers is drug pricing, which varies by country and can change rapidly as generics enter the market or as manufacturers negotiate with health systems. For patients, this means that access to the newest regimens can depend significantly on insurance coverage and geography, even when the clinical evidence clearly favors one approach.